Hot Investor Mandate: Early-Stage Focused Investment Firm Actively Seeks Medical Devices, Diagnostics, Digital Health, and Research Tools Based in USA

10 Feb

A venture capital company located in the USA manages 2 funds and makes equity investments into companies ranging from a few hundred thousand dollars to $2million with additional capital reserved for follow on rounds. The firm is looking for companies located throughout the United States and plans to make 4 new investments over the next 9-12 months.

The firm is looking for companies developing Medical Devices and Diagnostics, Healthcare IT products and Life Science Research Tools with an emphasis on fast to market low capital intense products that reduce the cost of delivering quality healthcare. The firm is open to all sub-sectors and indications in the Medical technology space except for those targeting diseases and disorders of the spine. The firm will invest in both seed and later stage companies.

The firm is looking for companies with skilled and experienced management teams. The firm generally looks to take a board seat into companies after investment and play and active role in the management. The firm is willing to invest in both public and privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Early Bird Rates at Digital RESI March 2022

3 Feb

By Rory McCann, Marketing Manager & Conference Producer, LSN

Digital RESI JPM is barely out of the rearview mirror at Life Science Nation (LSN), but that doesn’t mean Digital RESI March isn’t coming up fast. RESI is not meant to be a one-shot success story. It’s designed to follow the principles of early-stage fundraising:

1 It’s a numbers game.
2 It takes time.
3 It requires research, a compelling story, and strategic outreach and follow-up.

RESI returns five times each year, not only as a tool in the shed of investors seeking portfolio assets, but also as a platform for startups to connect, meet, and pitch to investors and strategic partners who are a fit for their product and stage of development. The rapid turnaround of events speaks to the importance of consistency and the speed necessary to progress with partnerships. This also means that the window for early-bird season is coming to a close.

Startups can save $200 when they register for Digital RESI March by February 18. RESI is priced competitively with the understanding that resources are tight while fundraising. Early bird rates invite founders to get involved early to start working with some of LSN’s powerful complimentary resources to enhance their RESI experience and support their outreach. See what Digital RESI JPM attendees have to say and contact us to learn more about our exclusive rates and upcoming free bootcamps to get 2022 fundraising off on the right foot!

“This was our first conference, and we were very pleased with the quality of the companies that we met and with the communications from the conference organizers.”

“I very much appreciate the ability to attend RESI conferences as an investor.”

“I like this platform and helpful LSN folks very much and feel LSN is doing an excellent job creating a friendly community for early-stage startups.”

resi-march-2022

Tech Hubs at RESI and Beyond

3 Feb

By Alexander Vassallo, Manager of Business Development West Coast (US), LSN

Life Science Nation (LSN)’s global network, built over the past decade, incorporates a host of exciting early-stage life science strategic partners, including Technology (Tech) Hubs. Due to the key role that Tech Hubs play in the early-stage life science arena, LSN has developed several Tech Hub-specific offerings to the central benefit of their constituents.

The first offering relates to a special 50% discount on standard 3-day registrations to any 2022 Redefining Early Stage Investments (RESI) partnering event – the nucleus of LSN’s global network partnerships. Provided the constituent has raised under $2M USD, they can attend RESI for $598, as opposed to the standard price of $1195. Constituents can partner with any number of the hundreds of active investors who attend RESI regularly, showcase their technology, and highlight why their company should be an investor’s top choice for 2022. For less than $600, this offer is rare in the life science partnering community, making it a no-brainer for cash-strapped businesses.

The second offer includes access to the LSN Investor Database. The LSN Investor Database helps startups raising their Seed to Series B funding rounds connect with active investors who are a right fit for their product and stage of development. The LSN Investor Database currently contains more than 10,000 global investors from over 2,500 investment firms across domains of therapeutics, medical devices, diagnostics, and digital health. When three, or more, tech hub constituents join, each constituent receives a four-month subscription, one free ticket to any 2022 RESI event, and a guaranteed slot in the Innovator’s Pitch Challenge (IPC) for $2,000 per startup. Individually, these components would cost $3,800, but through this Tech Hub Group Fundraising Package, constituents have even more to benefit from.

Finally, all Tech Hub partners that send at least one constituent to RESI in 2022 will receive a dedicated webpage for that respective conference. Tech Hubs can showcase all their organization has to offer by submitting materials to LSN including an organization description, introductory video, brochure, case studies, and more. LSN curates these materials into a dedicated webpage which grants an unparalleled opportunity for exposure with our network. This dedicated webpage is part of the Tech Hub Partnership Agreement, a free-of-cost arrangement between LSN and the Tech Hub that ensures maximum benefit for both parties.

Past RESI Tech Hubs

Tech Hub administrators and constituents alike can benefit from these special offers. If you’re interested in learning more, contact us, and our dedicated business development team is ready to see how we can be a meaningful stop along the way to fundraising success.

Want to learn more? The Business Development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International East Coast (USA) & China Midwest (USA)
& Canada
West Coast  (USA)
Alex
Greg Mannix
Vice President International Business Development, General Manager Europe
Book a Meeting
Email Me
Candice He
Vice President of Business Development, Global Investment Strategist
Book a Meeting
Email Me
Antoinette Lowre
Manager of Business Development
Book a Meeting
Email Me
Alexander Vassallo
Manager of Business Development
Book a Meeting
Email Me

resi-march-2022

Panels at Digital RESI March

3 Feb

By Karen Deyo, Director of Investor Research, Israel BD, LSN

The Redefining Early Stage Investment (RESI) conference series is, first and foremost, a partnering event. However, in addition to being partnering-centric, RESI is also designed to provide unfettered access to “the room where it happens” in the form of investor panels designed to provide valuable insight into what investors want in 2022.

Digital RESI March will feature 13 panels, with 10 panels featuring investors sharing their insights and giving tips to fundraising companies, as well as 3 panels featuring startups sharing their successful fundraising stories, how they achieved it, and what they’ve learned along the way. The investor panels range in focus from Seed Funds to Medtech Strategics, and focusing on different sectors, from Mental & Behavioral Health to Cell & Gene Therapy. Additionally, there will be AI and Longevity-focused panels, two areas of the life sciences with increasing focus.

RESI is first and foremost a partnering conference, but this content offers many startups keen strategies to help them avoid common pitfalls when approaching investors. Attendees can take the time to watch the sessions live and ask the panelists questions, or choose to watch the panels at a later date, with the panel recordings available on the Live Agenda up to three weeks after the conference ends.

If your New Year’s resolution was to kick off an early-stage fundraise, you’re not alone, but RESI provides the actionable steps to get from point (or series) A to B. Check out our panels below and register by February 18 to save $200!

Digital RESI March 2022 Panels
Tuesday
March 22
11 AM EST Early-Stage Therapeutics
Bringing the Newest Therapies to the Clinic
2 PM EST Digital Health & Wellness
Silver-Tech Focusing on Preventative Car
3 PM EST Seed Funds
Investing in the Earliest Stage Companies
4 PM EST Tales from the Road: AI Innovators on their Fundraising Journey
Wednesday
March 23
11 AM EST Age-Tech Devices
Seniors Embrace Innovative Medtech for Better Quality of Life
2 PM EST Medtech Strategics
Large Corporations Seeking External Innovation in MedTech
3 PM EST AI Drug Discovery and Development
How AI is Accelerating Therapeutic Advancement
4 PM EST Tales from the Road: Biotech and MedTech Innovators on their Fundraising Journey
Thursday
March 24
11 AM EST Precision Medicine
Improving Outcomes through a Patient-Tailored Approach
1 PM EST Cell & Gene Therapy
The Next Generation of Therapeutic Technologies
2 PM EST Defining AI Investment
AI-Exclusive Investors Share Their Perspectives
4 PM EST Tales from the Road: Age-Tech Innovators on their Fundraising Journey

resi-march-2022

Hot Investor Mandate: VC Firm Invests in Pre-Seed and Seed Stage Therapeutics, Diagnostics, and Life Science Tools with Strong Interest in Platform Technologies

3 Feb

A venture firm founded in 2015 with offices in USA and Israel. The firm invests in multiple sectors, including the life sciences, in pre-seed and seed stage companies; within healthcare, therapeutics, diagnostics and R&D tools companies developing platform technologies. The firm invests early, often acting as the first institutional capital, investing just after the initial stages of product development. The firm generally leads rounds, investing between $.5-5M in rounds no larger than ~$7M. While the firm has to this point invested in US and Israeli companies, it will also consider European and Canadian companies as well.

Within healthcare, the firm is interested in platform technologies in therapeutics and diagnostics/R&D tools. The firm is agnostic to indication and modality, and is looking for companies that have multiple avenues of development to reach the market. Previous investments include companies building CRISPR technologies, post-treatment monitoring, -omics-based drug development, CAR-T and high-throughput screening. The firm does not invest in digital health or medical devices.

The firm acts as a lead investor. Even though they invest early, the firm prefers that the company have at least two full time co-founders before investing. The firm does take a board seat after investing, and is an active investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Arm of a Leading Asian VC Firm Invests Up to $20M, Most Interested in Clinical Stage Therapeutics in Immuno-oncology, Ophthalmology, and More

3 Feb

A wholly owned subsidiary of a leading venture capital firm headquartered in Asia was established to focus on US-based biotechnology companies. The firm is interested in opportunities at all stages of development and can allocate between $500 K up to $20 M in equity investments, acting as a lead or follow on.

The firm is currently focusing on the areas of immuno-oncology, gene therapy, ophthalmology, and platform technologies. Previous investments include companies targeting clinical stage small molecule therapeutics for oncology, cyclic peptide drugs for immuno-modulation in chronic inflammatory diseases, and delivery methods and therapeutics for blinding diseases of the eye. The firm invests only in therapeutics, and is very open to investing in early-stage, pre-clinical assets. The firm has been working with a large network of universities and tech transfers to identify promising early-stage opportunities.

The story behind the company and management team is important to the firm. The firm looks for a cohesive business plan and strategy, and are especially interested in opportunities with potential to expand into the Asian market. The firm has a strong network of pharmaceuticals and investors in South Korea that can support market entry. The firm is open to both leading and co-investing, and seeks board representation when acting as the lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Canada-Based Investment Firm Actively Invests in Therapeutics, Diagnostics, and Healthcare Platforms and Later-Stage Devices and Digital Health Companies

3 Feb

A Canada-based venture capital firm is investing out of a fund that invests in both companies and other funds with aligned interests. The firm focuses on investments in three main sectors: Biopharmaceutical, Healthcare Platform & Services, and Technology (i.e., SAAS, Fintech). The firm provides initial investments at USD 3-5 million, and it will also reserve a further amount for follow-on financing and supports the startups in strategic partnerships. The firm is interested in pre-clinical to clinical-stage biotech companies. The firm invests primarily in North America but also opens to invest in Europe or China.

The firm is looking for new opportunities in the life science space, including therapeutics, diagnostics, and healthcare platforms. The firm’s investments to date have included companies developing in cell therapy, oncology, neuroscience, and drug-discovery platform. The firm is opportunistic in terms of sector, subsectors, and indications. The firm will also consider orphan drugs. Within medical devices and digital health, the firm will only consider companies that already have a USD 10 million minimum revenue. The firm will only co-invest and will prefer to co-invest with well-known lead investors.

The firm does not have specific requirements on companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.